false
OasisLMS
Catalog
2021 Annual Meeting Startup & Practice Management ...
Treatment of human bone marrow concentrate and bon ...
Treatment of human bone marrow concentrate and bone marrow stem cells with senolytic agents
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Katie Whitney, an MPH student in epidemiology and research specialist at the Stem and Filpon Research Institute, discusses innovative methods to improve the cell function of bone marrow aspirate concentrate (BMAC) and bone marrow-derived stem cells. Post-traumatic osteoarthritis is increasing in young adults, and orthobiologics have been used to reduce chronic inflammation. However, there is currently no consensus on the efficacy of BMAC for musculoskeletal tissue treatment. Aging and injury impact tissue regenerative potential through cellular decline and senescence. Whitney's group is investigating therapeutic approaches to improve musculoskeletal healing and delay osteoarthritis by removing senescent cells and inhibiting senescence-associated secretory phenotype factors. They are conducting clinical trials using the senolytic agent facet and in combination with BMAC. Validation and development of senescence detection using C12 FDG in bone marrow and peripheral blood are being explored. The study aims to detect senescence, remove senescent cells, and improve cell function in BMAC and mesenchymal stem cells. The ultimate goal is to support healthy aging in orthopedics.
Asset Caption
Dr. Kaitie Whitney
Keywords
Katie Whitney
epidemiology
bone marrow aspirate concentrate
musculoskeletal tissue treatment
senescence
×
Please select your language
1
English